DETROIT, Feb. 12, 2019 /PRNewswire/ -- Stratview Research announces the launch of a new market research report on Opportunities and Gaps in the Global Lung Cancer Prognosis Market By Treatment Algorithm in Different Regions, By Therapeutics, By Diagnostics, By Surgery, By Connected Health, By Nutritional Supplement and by Region (North America, Western Europe, Asia-Pacific, Latin America, Rest of the World): 2019-2025.
For the first time in market, one report in the healthcare industry exclusively touches upon the demands, gaps and opportunities of the global lung cancer market while covering Lung Cancer Diagnostics, Lung Cancer Therapeutics, Lung Cancer Nutritional supplement, Lung Cancer Surgery and Lung Cancer Connected Health Market. The management of Lung cancer varies with region, by decision makers, by site of treatment, by type of lung cancer, by age, by decision making process, by cost of therapy at each stage and by various other parameters. Why Lung Cancer? Because WHO and other health agencies consider it to be the number One killer across the world.
The Burning Questions This Report Will Answer:
- Over 1.5 million people worldwide die from lung cancer per year; why does the disease still has an extremely poor prognosis with all the modern technology?
- What are the options available for accurate prediction of lung cancer?
- Which market is more lucrative: pharma, diagnostics or surgery?
- Which technologies are available currently and how will the future technologies disrupt the market?
- What is the future of the top 10 best-selling drugs in this segment, will they stay or fade away?
- Among the class of drugs, will Angiogenesis Inhibitors take a dip in sales by 2025 or will it overtake the sales of drugs in the class Immune Checkpoint Inhibitors? What is the market for BRAF / MEK Inhibitors?
- Will the differential cost of therapeutics across regions impact the drug sales in North America versus APAC?
Lung Cancer Prognosis Market: Research Highlights
If we consider the lung cancer management market from the stakeholder's perspective, then drugs approved for 'Small Cell Lung Cancer' will not be applicable for 'Non-Small Cell Lung Cancer'. In the Small-Scale Lung Cancer Therapeutics, immunotherapy drugs will play a major role in the next 7 years and may grow at a CAGR of 7.4% globally, however the same class of drugs might grow at a CAGR of 10.6% in the Non-Small-Scale Lung Cancer Therapeutics Market in the same time period. The market had a potential of US$ 17.1 billion alone in 2018 and is likely to grow at a CAGR of 8.3% globally till 2025.
In the lung cancer diagnostics segment, Thermofischer, Roche, Biomerieux are few of the market leaders but are they going to get tougher competitions from the newbies such as Astraeus Technologies, Zebra Medical, Deton, Oncocyte and many more that are entering the specialized diagnostics market. It might be interesting to consider that while 50% of the oncologists decide (decision makers) the type of tests and the frequency of repeat tests, shared decision-making process is equally high among the Lung Cancer Management Market. The opportunity is huge, NSCLC cases accounts for 85% of the recorded lung cancer incidence worldwide, > 60% require diagnosis, medicine for maintenance, pain and other side effects.
Considering the complications and limitations in lung cancer surgery (not all patients are eligible), still the market is expected to grow steadily at a CAGR of 6.3%, during the forecast period (2019-2025). The demand for NSCLC surgery is high, thus the market size of 99%. In some cases, surgery is not recommended, when the tumor is found in proximity with the heart, the esophagus – the food pipe, the wind pipe and major blood vessels. The demand for NSCLC surgery is expected to grow rapidly with a CAGR of 6.3% over the course of next seven years.
The study on the lung cancer management market by Stratview also states that Lobectomy (sub segment under Lung Cancer Surgery) results in lowest recurrence rate and higher survival rate as compared to other surgery type. Hence, it is the highly referred type of surgery procedure for NSCLC cases. One of the companies, Auris is most promising in this segment and has a brighter future ahead. This segment also foresees competition from Chinese companies such as IFLYTEK who are strong contenders in the global market.
Among the different segments of global lung cancer management market, connected health or Apps for Lung cancer maintenance or management are few. However, the segment is promising, as researchers believe that App based software can help in treatment adherence, keeping track of medical records (insurance companies, medical centers). Developed markets such as the USA, the UK, Germany, France, Japan, China and Australia are the near-term opportunities for the connected health segment.
Lung cancer patients need nutritional supplements throughout their treatment phase followed by recovery and maintenance phase. The study also looks at the aspects of sales and marketing, buying patterns of end users which can help companies such as Abbott, Danone, Nestle, B Braun and more gauge the market and look at the changing preferences of the market in regions such as Asia Pacific, Europe and North America.
Finally, the report on lung cancer prognosis also focuses on the regional aspects and gives the reader the flexibility to consider between the global market or regions. It is imperative to look at this market as connected, as out of the prevalent cases of lung cancer, are potential candidates of diagnosis and of the diagnosed pool a higher percentage will require medication or surgery, there will be few drop outs and few gaps, more or less all the above will need apps or Healthcare IT products to monitor drug adherence, doctor access, and above all long term nutritional supplement.
Hence, readers may consider these inter-linked markets under the lung cancer management market and consider the opportunities that exist in each segment from 2019 to 2025.
Our reports offer high-quality insights and are the outcome of detailed research methodology comprising extensive secondary research, rigorous primary interviews with industry stakeholders and validation and triangulation with Stratview Research's internal database and statistical tools. More than 1,000 authenticated secondary sources, such as company annual reports, fact book, press release, journals, investor presentation, white papers, patents, and articles have been leveraged to gather the data. About 20 detailed primary interviews with the market players across the value chain in all four regions and industry experts have been executed to obtain both the qualitative and quantitative insights.
This report provides market intelligence in the most comprehensive way. The report structure has been kept such that it offers maximum business value. It provides critical insights into the market dynamics and will enable strategic decision making for the existing market players as well as those willing to enter the market. The following are the key features of the report:
- Market structure: Overview, industry life cycle analysis, supply chain analysis
- Market environment analysis: Growth drivers and constraints, Porter's five forces analysis, SWOT analysis
- Market trend and forecast analysis
- Market segment trend and forecast
- Competitive landscape and dynamics: Market share, Product portfolio, New product launches, etc.
- Attractive market segments and associated growth opportunities
- Emerging trends
- Strategic growth opportunities for the existing and new players
- Key success factors
- Future outlook
Stratview Research has number of high value market reports in the global healthcare industry. Please refer to the following link to browse through our reports:
Click Here for Other Reports from Stratview Research in the Healthcare Industry
Our related premium market report in the healthcare industry:
Opportunities & Gaps in the In Vitro Diagnostic Testing Market By Product (Instruments, Reagents), By Technology (Immunoassay, Clinical Chemistry, Molecular Diagnostics, Hematology, and Urinalysis, Microbiology), By Application (Diabetes, Infectious diseases, Oncology, Cardiology, Nephrology, and Other Diseases) By Type of Demand for Sample (Urine, Hair, and Oral), By Testing Facility (Hospital Laboratories, Independent Clinical Laboratories and Others), by Region (North America, Western Europe, Asia-Pacific, Latin America, Rest of the World).
Opportunities & Gaps in the Sepsis Diagnosis Market By Technology (Microbiology, Molecular Diagnostic, Immunoassay, and Biomarkers), By Type of Testing (Blood Culture Media, and Instruments), By Mode of Testing (Automated, Semi-Automated), By Site of Testing (Laboratory Based, Patient Bed Side (POC)), By Type of Sepsis (Pathogen) (Bacterial, Fungal), By Testing Facility (Hospitals, Clinics, and Others), By Region (North America, Western Europe, Asia-Pacific, Latin America, Rest of the World).
About Stratview Research
Stratview Research is a global market intelligence firm providing wide range of services including syndicated market reports, custom research and sourcing intelligence across industries, such as Advanced Materials, Aerospace & Defense, Automotive & Mass Transportation, Consumer Goods, Construction & Equipment, Electronics and Semiconductors, Energy & Utility, Healthcare & Life Sciences, and Oil & Gas.
We have a strong team of industry veterans and analysts with an extensive experience in executing custom research projects for mid-sized to Fortune 500 companies, in the areas of Market Assessment, Opportunity Screening, Competitive Intelligence, Due Diligence, Target Screening, Market Entry Strategy, Go to Market Strategy, and Voice of Customer studies.
Stratview Research is a trusted brand globally, providing high quality research and strategic insights that help companies worldwide in effective decision making.
SOURCE Stratview Research